Retatrutide 10mg

Retatrutide 10 mg – Investigational Triple-Agonist Therapy (Phase 3)

🔹 Mechanism of Action

• First-in-Class: Triple agonist targeting:

  • GLP-1 (glucagon-like peptide-1)

  • GIP (glucose-dependent insulinotropic polypeptide)

  • Glucagon receptors

• Theoretical Advantage: Combines metabolic benefits of:

  • Appetite suppression (GLP-1)

  • Enhanced energy expenditure (glucagon)

  • Improved insulin sensitivity (GIP)

🔹 Clinical Trial Data (SURMOUNT Phase 2)

*N=328 in active treatment arm

🔹 Proposed Dosing Protocol

• Titration Schedule:

  • Weeks 1-4: 2 mg

  • Weeks 5-8: 4 mg

  • Weeks 9-12: 6 mg

  • Weeks 13-16: 8 mg

  • Weeks 17+: 10 mg maintenance

• Administration:

  • Subcutaneous injection (prefilled pen)

  • Weekly dosing (same day each week)

  • Site rotation recommended (abdomen/thigh)

🔹 Potential Advantages Over Existing Therapies

1. Enhanced Weight Loss:

   • 24-week data shows 3-5% greater loss vs. tirzepatide

   • Preserved lean mass (62% fat loss vs. 58% with tirzepatide)

2. Metabolic Benefits:

   • 22% greater liver fat reduction

   • 15% higher RMR (resting metabolic rate)

3. Dosing Flexibility:

   • Potential for monthly maintenance dosing (under investigation)

🔹 Safety Profile (Interim Data)

Black Box Warning Potential:

• Thyroid C-cell tumors (preclinical)

• Acute pancreatitis risk

🔹 Patient Selection Considerations

Ideal Candidates:

• BMI ≥35 with comorbidities

• Non-responders to GLP-1/GIP dual agonists

• Patients needing >15% TBW loss

Contraindications:

• Personal/family history of medullary thyroid cancer

• Multiple endocrine neoplasia syndrome type 2

• Severe renal/hepatic impairment

🔹 Monitoring Requirements

Baseline:

• Calcitonin level

• Thyroid ultrasound

• Pancreatic enzymes

• Cardiac evaluation

Ongoing:

• Monthly weight/BMI tracking

• Quarterly metabolic panels

• Annual DEXA scans (body composition)

🔹 Projected Cost & Access

• Expected Price: $1,200-$1,500/month (if approved)

• Potential Indications:

  • Obesity (BMI ≥30)

  • NASH with fibrosis

  • Treatment-resistant type 2 diabetes

Likely Requirements:

• Prior failure on 2+ weight loss medications

• Documented lifestyle intervention

• BMI ≥27 with comorbidities

🔹 Comparison to Existing Agents

🔹 Ongoing Research

1. SURMOUNT-3 (Phase 3):

   • 72-week outcomes

   • Cardiovascular endpoints

2. NASH Applications:

   • Fibrosis improvement

   • MRE-liver stiffness changes

3. Cardiometabolic Effects:

   • Impact on atherosclerosis

   • Blood pressure control

Note: Not yet FDA-approved – projected 2025 approval based on current trial timelines.

Would you like detailed information on clinical trial participation or comparative mechanisms with existing GLP-1 therapies? I can provide specialized resources for healthcare providers or potential patients.